De­spite tri­al dis­con­tin­u­a­tions, Rhythm’s ge­net­ic obe­si­ty drug ef­fec­tive in an­oth­er rare in­di­ca­tion 

Fol­low­ing a sec­ond FDA OK for its ge­net­ic obe­si­ty drug last month for pa­tients with Bardet-Biedl syn­drome, Rhythm Phar­ma­ceu­ti­cals con­tin­ues its quest to ex­pand the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER